Literature DB >> 2262373

Influence of radiation on the blood-brain barrier and optimum time of chemotherapy.

D X Qin1, R Zheng, J Tang, J X Li, Y H Hu.   

Abstract

A pilot study of the destructive effects of radiation on the blood-brain barrier (BBB) was made on 14 patients with localized and limited brain tumors by 99MTc-GH imaging from August 1988 to November 1989. Count/pixel data were obtained from the unirradiated, irradiated, and tumor areas before and after radiotherapy of 30-40 Gy. It was observed that, a) the BBB in the unirradiated area outside the radiation portal was not changed, b) the degree of destructive effect on the BBB in the irradiated normal area was directly proportional to the radiation dose. For 30-40 Gy, the count/pixel change enhances to average 24.7% [(147.6-118.4)/118.4], and c) the BBB in the tumor area is partially destroyed on an average of 22.1% [(206.8-169.4)/169.4] by the tumor. The radiotherapy further enhances this effect to an average of 74.7% [(206.8-118.4)/118.4]. Case 3 showed that before radiation, the degree of destructive effect on the BBB in the tumor area was 22% [(167-137)/137] higher than normal brain tissue. After a dose of 30 Gy of irradiation, it increased to 76.7% [(242-137)/137]; 8 months later it decreased to 17% [(160.3-137)/137]. It has been proven that the BBB can recover at least partially. Based on these observations, the authors believe that in the combined treatment of operated brain tumors, radiotherapy should precede chemotherapy so as to enhance the destruction of the BBB, facilitating the incorporation of drugs into the tumor. The dose at which to start chemotherapy is 20-30 Gy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2262373     DOI: 10.1016/0360-3016(90)90364-p

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  28 in total

1.  Targeting microparticles to select tissue via radiation-induced upregulation of endothelial cell adhesion molecules.

Authors:  Mohammad F Kiani; Hong Yuan; Xin Chen; Lee Smith; M Waleed Gaber; Douglas J Goetz
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

2.  Gadolinium deposition in the brain: association with various GBCAs using a generalized additive model.

Authors:  Sohi Bae; Ho-Joon Lee; Kyunghwa Han; Yae-Won Park; Yoon Seong Choi; Sung Soo Ahn; Jinna Kim; Seung-Koo Lee
Journal:  Eur Radiol       Date:  2017-01-12       Impact factor: 5.315

Review 3.  Therapeutic strategies to improve drug delivery across the blood-brain barrier.

Authors:  Tej D Azad; James Pan; Ian D Connolly; Austin Remington; Christy M Wilson; Gerald A Grant
Journal:  Neurosurg Focus       Date:  2015-03       Impact factor: 4.047

Review 4.  Do anticancer agents reach the tumor target in the human brain?

Authors:  M G Donelli; M Zucchetti; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Apoptosis imaging for monitoring DR5 antibody accumulation and pharmacodynamics in brain tumors noninvasively.

Authors:  Thomas G Weber; Franz Osl; Anja Renner; Thomas Pöschinger; Stefanie Galbán; Alnawaz Rehemtulla; Werner Scheuer
Journal:  Cancer Res       Date:  2014-02-07       Impact factor: 12.701

6.  ACNU-cisplatin continuous infusion chemotherapy as salvage therapy for recurrent glioblastomas: phase II study.

Authors:  Ho-Shin Gwak; Sang-Min Youn; Austin-Hyuk Kwon; Seung Hoon Lee; Jong Hyun Kim; Chang Hun Rhee
Journal:  J Neurooncol       Date:  2005-11       Impact factor: 4.130

Review 7.  Magnetic hyperthermia therapy for the treatment of glioblastoma: a review of the therapy's history, efficacy and application in humans.

Authors:  Keon Mahmoudi; Alexandros Bouras; Dominique Bozec; Robert Ivkov; Constantinos Hadjipanayis
Journal:  Int J Hyperthermia       Date:  2018-02-06       Impact factor: 3.914

8.  Conductive interstitial hyperthermia in the treatment of intracranial metastatic disease.

Authors:  C J Moran; J A Marchosky; F J Wippold; J A DeFord; N E Fearnot
Journal:  J Neurooncol       Date:  1995-10       Impact factor: 4.130

Review 9.  Targeted delivery of antibody-based therapeutic and imaging agents to CNS tumors: crossing the blood-brain barrier divide.

Authors:  Ann-Marie Chacko; Chunsheng Li; Daniel A Pryma; Steven Brem; George Coukos; Vladimir Muzykantov
Journal:  Expert Opin Drug Deliv       Date:  2013-06-11       Impact factor: 6.648

10.  Activity of Eribulin Mesylate in Brain Metastasis from Breast Cancer: A Stone in a Pond?

Authors:  Giovanna Catania; Paola Malaguti; Simona Gasparro; Francesco Cognetti; Antonello Vidiri; Alessandra Fabi
Journal:  Oncology       Date:  2018-07-24       Impact factor: 2.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.